UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Neoadjuvant treatments for triple-negative breast cancer (TNBC)

Annals of oncology, 2012-08, Vol.23 Suppl 6, p.vi35-vi39

2012

Volltextzugriff (PDF)

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial

Annals of oncology, 2013-11, Vol.24 (11), p.2786-2793

2013

Volltextzugriff (PDF)

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

Annals of oncology, 2018-12, Vol.29 (12), p.2341-2347

2018

Volltextzugriff (PDF)

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)

Annals of oncology, 2013-12, Vol.24 (12), p.2978-2984

2013

Volltextzugriff (PDF)

Early prediction of pathologic response to neoadjuvant therapy in breast cancer: Systematic review of the accuracy of MRI

Breast (Edinburgh), 2012-10, Vol.21 (5), p.669-677

2012

Volltextzugriff (PDF)

Effective oral chemotherapy for breast cancer: pillars of strength

Annals of oncology, 2008-02, Vol.19 (2), p.212-222

2008

Volltextzugriff (PDF)

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006

Annals of oncology, 2007-12, Vol.18 (12), p.1927-1934

2007

Volltextzugriff (PDF)

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy

Annals of oncology, 2015-01, Vol.26 (1), p.95-100

2015

Volltextzugriff (PDF)

Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer

Annals of oncology, 2016-06, Vol.27 (6), p.1029-1034

2016

Volltextzugriff (PDF)

Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro)

Annals of oncology, 2014-01, Vol.25 (1), p.81-89

2014

Volltextzugriff (PDF)

Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer

Breast cancer research and treatment, 2018-02, Vol.168 (1), p.179-187

2018

Volltextzugriff (PDF)

Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients—a double-blind, randomized study

Annals of oncology, 2007-04, Vol.18 (4), p.689-693

2007

Volltextzugriff (PDF)

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

Annals of oncology, 2019-08, Vol.30 (8), p.1279-1288

2019

Volltextzugriff (PDF)

Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer

Annals of oncology, 2013-09, Vol.24 (9), p.2316-2324

2013

Volltextzugriff (PDF)

Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer—comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial

Annals of oncology, 2009-02, Vol.20 (2), p.258-264

2009

Volltextzugriff (PDF)

Preoperative therapy: what, when and for whom?

Annals of oncology, 2008-07, Vol.19 (suppl-5), p.v113-v116

von Minckwitz, G.

2008

Volltextzugriff (PDF)

BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial

Breast cancer research and treatment, 2017-12, Vol.166 (3), p.775-785

2017

Volltextzugriff (PDF)

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Annals of oncology, 2016-08, Vol.27 (8), p.1519-1525

2016

Volltextzugriff (PDF)

Optimizing taxane use in MBC in the emerging era of targeted chemotherapy

Critical reviews in oncology/hematology, 2013-03, Vol.85 (3), p.315-331

2013

Volltextzugriff (PDF)

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial

British journal of cancer, 2012-09, Vol.107 (6), p.956-960

2012

Volltextzugriff (PDF)

Breast cancer patients' expectations in respect of the physician–patient relationship and treatment management results of a survey of 617 patients

Annals of oncology, 2007-03, Vol.18 (3), p.479-484

2007

Volltextzugriff (PDF)

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

Annals of oncology, 2013-02, Vol.24 (2), p.398-405

2013

Volltextzugriff (PDF)

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study

Annals of oncology, 2010-11, Vol.21 (11), p.2188-2194

2010

Volltextzugriff (PDF)

The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial

British journal of cancer, 2006-06, Vol.94 (11), p.1615-1620

2006

Volltextzugriff (PDF)

Reply to Ki67 in breast cancer: a useful prognostic marker

Annals of oncology, 2014-02, Vol.25 (2), p.542-543

2014

Volltextzugriff (PDF)

1 – 25 von 141

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

Zeitschrift / SerieOnkologie

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(137)
Mit Volltextzugriff
(114)

Publikationsform

Sprache

Englisch
(119)
Deutsch
(22)

Erscheinungsjahr

n.n

Thema

Humans
(139)
Female
(133)
Science & Technology
(113)
Life Sciences & Biomedicine
(112)
Oncology
(90)
Breast Neoplasms - Drug Therapy
(79)
Middle Aged
(74)
Breast Cancer
(69)
Adult
(65)
Biological And Medical Sciences
(61)
Breast Neoplasms - Pathology
(61)
Medical Sciences
(60)
Tumors
(57)
Aged
(52)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(51)
Gynecology. Andrology. Obstetrics
(44)
Mammary Gland Diseases
(42)
Pharmacology. Drug Treatments
(40)
Chemotherapy, Adjuvant
(39)
Treatment Outcome
(36)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Neoadjuvant treatments for triple-negative breast cancer (TNBC)

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)

Early prediction of pathologic response to neoadjuvant therapy in breast cancer: Systematic review of the accuracy of MRI

Effective oral chemotherapy for breast cancer: pillars of strength

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy

Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer

Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro)

Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer

Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients—a double-blind, randomized study

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer

Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer—comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial

Preoperative therapy: what, when and for whom?

BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Optimizing taxane use in MBC in the emerging era of targeted chemotherapy

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial

Breast cancer patients' expectations in respect of the physician–patient relationship and treatment management results of a survey of 617 patients

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study

The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial

Reply to Ki67 in breast cancer: a useful prognostic marker

Aktive Filter

Suchergebnisse filtern